2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168987
    Netanasvir 2007900-70-9
    Netanasvir, a NS5A inhibitor, possesses antiviral activity. Netanasvir can be used in the study for HCV study.
    Netanasvir
  • HY-168991
    Laporolimus 1504576-27-5
    Laporolimus is an immunosuppressant.
    Laporolimus
  • HY-168993
    BRCA2-IN-2
    BRCA2-IN-2 (Compound 3i) has a strong binding affinity to the BRCA2 protein. BRCA2-IN-2 can inhibit the proliferation of breast cancer cells and scavenge DPPH free radicals. BRCA2-IN-2 has anti-tumor and antioxidant activities.
    BRCA2-IN-2
  • HY-168997
    CB1R agonist 1
    CB1R agonist 1 (Compound '1350') is a potent full agonist of the cannabinoid-1 receptor (CB1R), with a Ki value of 0.95 nM. CB1R agonist 1 exhibits significant pain-reducing effects in multiple pain models, including acute heat pain, inflammatory pain, and neuropathic pain.
    CB1R agonist 1
  • HY-169005
    Cbl-b-IN-27
    Cbl-b-IN-27 is a casitas B-lymphoma proto-oncogene-b (Cbl-b) inhibitor with an IC50 value of 7 nM. Cbl-b-IN-27 is promising for research of effector T cell function, T cell, natural killer (NK) cell and B cell activation regulation.
    Cbl-b-IN-27
  • HY-169007
    STAT3-IN-34
    STAT3-IN-34 (Compound 15E) is an inhibitor for STAT3, and inhibits the nuclear translocation and transcriptional regulator activity of STAT3. STAT3-IN-34 inhibits the proliferation of cell HaCaT with IC50 of 0.008 μM. STAT3-IN-34 inhibits IL-17A expression and ameliorates Imiquimod (HY-B0180)-induced psoriasis in mice.
    STAT3-IN-34
  • HY-169024
    GSK-3β inhibitor 19
    GSK-3β inhibitor 19 (compound 36) is a GSK-3β inhibitor, with IC50 of 70 nM. GSK-3β inhibitor 19 can be used in anti-inflammatory and Alzheimer's disease related research.
    GSK-3β inhibitor 19
  • HY-169043
    (±)7(S),8(R)-EDT 355016-21-6
    (±)7(S),8(R)-EDT is an isomer of 7,8-EDT.
    (±)7(S),8(R)-EDT
  • HY-169052
    Cyy-272 2644673-01-6
    Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy.
    Cyy-272
  • HY-169055
    SARS-CoV-2 Mpro-IN-25 2205006-23-9
    SARS-CoV-2 Mpro-IN-25 (Compound 3a) is a SARS-CoV-2 protease inhibitor with an IC50 value of 0.26 μM. SARS-CoV-2 Mpro-IN-25 exhibits antiviral activity and can be used in pneumonia-related research.
    SARS-CoV-2 Mpro-IN-25
  • HY-169057
    BI1543673
    BI1543673 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. BI1543673 can reduce the inflammatory response stimulated by TLR4 and TLR7/8 in human lung tissue. BI1543673 can decrease inflammatory signaling in a mouse model of lung inflammation induced by LPS.
    BI1543673
  • HY-169059
    Ferroptosis-IN-12
    Ferroptosis-IN-12 (Cpd-A1) is a ferroptosis inhibitor. Ferroptosis-IN-12 exhibits effective ferroptosis inhibition in Erastin (HY-15763)-treated mouse tubular epithelial cells (mTECs) and improves kidney function, alleviates renal tubular damage, and reduces inflammation in a dose-dependent manner in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). Ferroptosis-IN-12 demonstrates good plasma stability and high distribution in kidney tissues in pharmacokinetic studies in mice. Ferroptosis-IN-12 holds promise for research in the field of acute kidney injury (AKI).
    Ferroptosis-IN-12
  • HY-169103
    Neuroprotective agent 5
    Neuroprotective agent 5 (compound 28) is a brain permeabilizing agent with anti-neuritis, anti-oxidative damage and neuroprotective effects. Neuroprotective agent 5 exhibits a potent NO inhibitory effect (EC50=0.49 μM), inhibits the release of proinflammatory factors PGE2 and TNF-α, downregulates the expression of iNOS and COX-2 proteins, and promotes the polarization of BV-2 cells from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype. In addition, Neuroprotective agent 5 can also inhibit acetylcholinesterase (AChE) activity and Aβ42 aggregation in a dose-dependent manner. Neuroprotective agent 5 can be used for the study of Alzheimer's disease.
    Neuroprotective agent 5
  • HY-169115
    PD-0299685 313651-33-1
    PD-0299685 is a potent Ca2+ channel α2δ ligand. PD-0299685 is promising for research of refractory genito-urinary pain and interstitial cystitis/bladder pain syndrome.
    PD-0299685
  • HY-169153
    Cot inhibitor-3 1984784-12-4
    Cot inhibitor-3 (Compound 33) is a potent and selective cancer osaka thyroid (COT) kinase inhibitor, with an IC50 of 4 nM. Cot inhibitor-3 can be used to prevent inflammation-driven lameness.
    Cot inhibitor-3
  • HY-169177
    JNK-1-IN-4 3047795-60-5
    JNK-1-IN-4 (Compound E1) is an inhibitor for JNK, that inhibits JNK-1, JNK-2 and JNK-3 with IC50s of 2.7, 19.0 and 9.0 nM, respectively. JNK-1-IN-4 inhibits the phosphorylation of c-Jun, and reduces the expression of TGF-β1-induced EMT marker proteins, such as fibronectin and α-SMA. JNK-1-IN-4 exhibits good pharmacokinetic characteristics with a bioavailability of 69%. JNK-1-IN-4 exhibits anti-fibrotic effect in Bleomycin (HY-17565)-induced mice idiopathic pulmonary fibrosis models.
    JNK-1-IN-4
  • HY-169192
    BAR-2227 2409154-23-8
    BAR-2227 (compound 3a) is a FXR agonist and LIFR inhibitor. BAR-2227 can be used to study liver fibrosis and inflammation.
    BAR-2227
  • HY-169226
    HDAC6-IN-51 2994634-78-3
    HDAC6-IN-51 (Compound 7e) is a selective HDAC6 inhibitor with an IC50 value of 42.9 nM. HDAC6-IN-51 exhibits good anti-lung fibrosis activity.
    HDAC6-IN-51
  • HY-169227
    NLRP3-IN-55
    NLRP3-IN-55 (Compound 19) is a potent NLRP3 inhibitor (IC50 = 0.34 μM). NLRP3-IN-55 directly targets the NLRP3 protein (KD = 0.45 μM), blocking the assembly and activation of the NLRP3 inflammasome, leading to anti-inflammatory effects and inhibition of cellular pyroptosis.
    NLRP3-IN-55
  • HY-169263
    AC10142A 2963581-29-3
    AC10142A is a selective Adenylyl Cyclase Type 1 inhibitor with IC50 of 0.26 μM. AC10142A can be used to study pain models.
    AC10142A
Cat. No. Product Name / Synonyms Application Reactivity